Abbott logo
  • Brands
  • Offerings
  • Solutions
  • Knowledge Center



PROFESSIONAL PROFILE


Q&A

HOW HAS YOUR PROFESSIONAL JOURNEY LED TO YOUR CURRENT ROLE WITHIN ABBOTT?

AMY PICHORA: From the beginning, my career has been driven by my desire to use my total skillset – obtained from working for healthcare institutions from trauma centers to hospital networks to reference laboratories – to help labs continuously improve their processes, deliver better patient care, and become great places to work. Working at Abbott has enabled me to grow and evolve while staying true to my original mission of helping labs elevate performance.

ON AVERAGE, HOW MANY LABORATORY WORKFLOWS DO YOU OBSERVE ON AN ANNUAL BASIS AND HOW DOES THIS EXPOSURE SHAPE YOUR APPROACH TO FUTURE ENGAGEMENTS?

AMY PICHORA: I manage a team of nine Technical Solutions Designers who support laboratories in Canada, Mexico, Columbia, Brazil and Argentina. This affords me the opportunity to become intimately involved with over 90 different sites, across the full spectrum of lab profiles, each year.  

Our analysis draws on multiple data sources. It’s not just about what we observe. We converse with staff. We use our LEAN Six Sigma methodologies to enhance data collection. This multi-faceted approach gives us an actionable picture of what’s going on in the lab.

Because our team has been fortunate to be exposed to a variety of labs and workflows, we’re able to identify non-value-added processes. I’m referring here to situations in which a lab is doing something a certain way not because it’s the best way to do it, but because that’s how it’s always been done – a phenomena that is sometimes referred to as “the Hidden Factory.” We uncover these Hidden Factories and help labs use more efficient processes, which in turn leads to elevated performance.

WHAT MARKET DYNAMICS DO YOU SEE AS BEING THE MOST IMPACTFUL FOR THE LABORATORY – TODAY AND TOMORROW?

AMY PICHORA: While each market has its own unique landscape, we see two common trends that are impacting lab operations. One is consolidation. For example, in Canada, we see main hospital labs looking at their smaller satellite labs and trying to determine how they can operate more efficiently. A second dynamic that we see across markets is downward pressure on the cost of care. For labs, this means finding ways to be more efficient, especially with respect to patient care.

WHAT SHOULD LABORATORIES BE THINKING ABOUT AND DOING TO BE BETTER PREPARED FOR THESE DYNAMICS TODAY – AND IN YEARS AHEAD?

AMY PICHORA: To address market dynamics like consolidation and cost pressure, labs need to view their operations holistically. You need to see the big picture and focus on the elements that add the most value. This starts with having someone who is responsible for studying the lab’s end-to-end process or “value stream.” It also requires solutions that support this kind of big picture analysis and identify the critical metrics that drive continuous improvement. The better visibility you have to your operation as a whole, the more effectively you can plan to adapt to disruptive changes in the marketplace. That’s what future proofing is all about. 

TO ADDRESS MARKET DYNAMICS LIKE CONSOLIDATION AND COST PRESSURE, LABS NEED TO VIEW THEIR OPERATIONS HOLISTICALLY. THEY NEED TO SEE THE BIG PICTURE RATHER THAN GETTING CAUGHT UP IN DETAILS. THIS STARTS WITH HAVING SOMEONE WHO IS RESPONSIBLE FOR STUDYING THE LAB’S END-TO-END PROCESS OR “VALUE STREAM".

SIGN UP FOR OUR NEWSLETTER

Sign up to receive the next edition of Healthcare Catalyst where we bring you the latest information, insights, ideas and innovative solutions to improve healthcare through laboratory medicine.

Already an Abbott subscriber? You'll receive new issues of Healthcare Catalyst automatically, no need to sign up.

LATEST ARTICLES

  • FUTURE PROOFING YOUR LAB

    Laboratorio Clínico Toledo (Lab Toledo) is the largest laboratory in the Caribbean. Take a look inside Lab Toledo's 'future proofing' initiative and discover how the laboratory maintains market leadership and pivoted to meet Puerto Rico's need for COVID-19 testing.

    Read More
  • THINKING IT THROUGH

    The COVID-19 pandemic has made it clearer than ever that future proofing your lab means being positioned to adapt to ever-changing market conditions. In this interview, you’ll find useful insights on building agility and flexibility into laboratory infrastructure and operating culture.

    Read More
  • SMART THINKING

    This article illuminates market dynamics that could impact your laboratory in the coming years – and offers advice on how to address them. The focus is on setting SMART goals and putting a metrics framework around continuous improvement.

    Read More
  • NEVER STOP LEARNING

    This article presents a unique and nuanced perspective on some of the key dynamics facing clinical laboratories, along with thoughts on how continuous learning and collaboration inform effective strategic planning.

    Read More

© 2022 Abbott, Abbott Park, Illinois, U.S.A.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the products or services of the company.

All Alinity hq, CELL-DYN Ruby, CELL-DYN Sapphire and CELL-DYN Emerald 22 AL are Class I laser products. ACCELERATOR a3600 is a Class II laser product.

The Alinity, ACCELERATOR and CELL-DYN systems are intended for performing in vitro diagnostic assays on samples of human origin (blood, urine). Read the instructions in the system manuals and labeling and/or reagent instructions carefully.

ADD-137615-GBL-EN